First-Line Oral Antihypertensive Medications for Adults with Hypertension
For most adults with hypertension, initiate treatment with a thiazide or thiazide-like diuretic (preferably chlorthalidone), an ACE inhibitor or ARB, or a long-acting calcium channel blocker—these four drug classes have the strongest evidence for reducing cardiovascular mortality and morbidity. 1
Recommended First-Line Monotherapy Options
The following drug classes are recommended as first-line agents based on high-quality evidence 2, 3:
- Thiazide/thiazide-like diuretics (Grade A) - with longer-acting agents like chlorthalidone preferred over hydrochlorothiazide (Grade B)
- ACE inhibitors (Grade B) - except in Black patients where they are less effective
- Angiotensin receptor blockers (ARBs) (Grade B)
- Long-acting calcium channel blockers (Grade B)
- Beta-blockers (Grade B) - only in patients younger than 60 years; NOT recommended as first-line in patients ≥60 years (Grade A)
Special Considerations by Patient Population
Black Patients
For Black adults with hypertension, initiate therapy with a thiazide-type diuretic or calcium channel blocker 4, 5. ACE inhibitors are notably less effective in this population for preventing stroke and heart failure compared to CCBs 4.
Stage 2 Hypertension (BP ≥140/90 mm Hg or >20/10 mm Hg above target)
Begin with combination therapy using two first-line agents from different classes, preferably as a single-pill combination 4, 6. Recommended combinations include:
- ACE inhibitor + calcium channel blocker (Grade A)
- ARB + calcium channel blocker (Grade B)
- ACE inhibitor or ARB + diuretic (Grade B)
Never combine an ACE inhibitor with an ARB - this combination is not recommended due to potential for harm (Grade A) 2, 4.
Comparative Effectiveness Evidence
High-quality evidence demonstrates that thiazide diuretics, particularly chlorthalidone, provide superior outcomes compared to other first-line agents 4, 7, 8:
- Thiazides vs. Beta-blockers: Thiazides reduce total cardiovascular events (ARR 0.6%) and withdrawals due to adverse effects (ARR 2.2%) 7
- Thiazides vs. Calcium Channel Blockers: Thiazides reduce total cardiovascular events (ARR 1.0%) and heart failure (ARR 1.2%) 7
- Thiazides vs. ACE Inhibitors: Thiazides reduce stroke slightly (ARR 0.6%) and withdrawals due to adverse effects (ARR 1.0%) 7
- Thiazides vs. Alpha-blockers: Thiazides substantially reduce total cardiovascular events (ARR 3.1%) and heart failure (ARR 2.6%) 7
Critical Pitfalls to Avoid
Do not use beta-blockers as first-line therapy in patients ≥60 years (Grade A) - they are less effective than other agents for stroke prevention 2, 3
Do not use alpha-blockers as first-line agents (Grade A) - they are less effective for CVD prevention than thiazides 2, 4
Avoid hypokalemia with thiazide monotherapy (Grade C) - monitor potassium levels 2
Exercise caution combining non-dihydropyridine CCBs with beta-blockers (Grade D) 2
Treatment Targets
Target blood pressure is <130/80 mm Hg for most adults 1, 5. For patients with known cardiovascular disease, the systolic target of <130 mm Hg has strong evidence (Grade A) 1. For those without CVD but with high cardiovascular risk, diabetes, or chronic kidney disease, a systolic target <130 mm Hg is conditionally recommended 1.
Practical Implementation
For stage 1 hypertension (130-139/80-89 mm Hg): Start with single-agent therapy, titrate dose, and add sequential agents as needed 4, 6.
For stage 2 hypertension or high-risk patients: Initiate with two-drug combination therapy, preferably as a single-pill combination to improve adherence 1, 6. Single-pill combinations reduce systolic BP by an additional 4 mm Hg compared to separate pills 9.
Monthly follow-up is recommended after initiation or medication changes until target BP is achieved, then every 3-5 months for patients under control 1.